Company research / TXG

10x Genomics, Inc. (TXG)

CIK 0001770787 · Nasdaq · Laboratory Analytical Instruments

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, 10x Genomics, Inc. reported revenue of $642.82M. Revenue grew 5.2% from the prior annual period.

Key ratios (year ended 2025-12-31)

69.1%
Gross margin
-9.5%
Operating margin
-6.8%
Net margin
-5.5%
Return on year-end equity
5.2%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 4 · 2026-09-03

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.